News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Evolus
< Previous
1
2
3
4
Next >
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
June 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports First Quarter 2023 Results and Provides Business Update
May 09, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
January 18, 2023
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Extends Term of Credit Facility with Pharmakon Advisors
December 08, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in November Conferences
November 02, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
October 04, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
September 21, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Announces Inducement Grants for New Chief Financial Officer
September 06, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Appoints Sandra Beaver as Chief Financial Officer
August 30, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
August 24, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports Second Quarter 2022 Results and Provides Business Update
August 02, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report Second Quarter 2022 Results and Provide Business Update
July 19, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
July 19, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
July 12, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
June 02, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
May 18, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 11, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus Reports First Quarter 2022 Results and Provides Business Update
May 10, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
Evolus to Report First Quarter 2022 Results and Provide Business Update
April 26, 2022
From
Evolus
Via
Business Wire
Tickers
EOLS
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Close